Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 3/2020

01-06-2020 | Insulinoma | Review

Insulinoma-associated protein 1 (INSM1): a potential biomarker and therapeutic target for neuroendocrine tumors

Authors: B. Mahalakshmi, Rathinasamy Baskaran, M. Shanmugavadivu, Ngoc Tuan Nguyen, Bharath Kumar Velmurugan

Published in: Cellular Oncology | Issue 3/2020

Login to get access

Abstract

Background

Insulinoma-associated protein 1 (INSM1), a transcriptional regulator with a zinc-finger DNA-binding domain, has been validated as a cytoplasmic marker for neuroendocrine differentiation of tumor cells. Next to its abundant expression in the fetal pancreas, it is expressed in brain tumors, pheochromocytomas, medullary thyroid carcinomas, insulinomas and pituitary and small-cell lung carcinomas. INSM1 is not expressed in normal adult tissues and/or most non-neuroendocrine tumors. It regulates various downstream signaling pathways, including the Sonic Hedgehog, PI3K/AKT, MEK/ERK1/2, ADK, p53, Wnt, histone acetylation, LSD1, cyclin D1, Ascl1 and N-Myc pathways. Although INSM1 appears to be a subtle and specific biomarker for neuroendocrine tumors, its role in tumor development has remained unclear.

Conclusions

Here, we highlight INSMI expression, as well as its diagnostic significance and use as a therapeutic target in various neuroendocrine tumors. Targeting signaling pathways or gene expression alterations associated with INSM1 expression may be instrumental for the design of novel therapeutic strategies for neuroendocrine tumors.
Literature
1.
E.F. Rodriguez, J.J. Fite, S. Chowsilpa, Z. Maleki, Insulinoma-associated protein 1 immunostaining on cytology specimens: an institutional experience. Hum. Pathol. 85, 128–135 (2019)PubMed
2.
Y. Goto, M.G. Desilva, A. Toscani, B.S. Prabhakar, A.L. Notkins, M.S. Lan, A novel human insulinoma-associated cDNA, Ia-1, encodes a protein with zinc-finger DNA-binding motifs. J. Biol. Chem. 267, 15252–15257 (1992)PubMed
3.
W.D. Liu, H.W. Wang, M. Muguira, M.B. Breslin, M.S. Lan, INSM1 functions as a transcriptional repressor of the neuroD/beta2 gene through the recruitment of cyclin D1 and histone deacetylases. Biochem. J. 397, 169–177 (2006)
4.
M.B. Breslin, M. Zhu, A.L. Notkins, M.S. Lan, Neuroendocrine differentiation factor, IA-1, is a transcriptional repressor and contains a specific DNA-binding domain: identification of consensus IA-1 binding sequence. Nucleic Acids Res. 30, 1038–1045 (2002)PubMedPubMedCentral
5.
M.S. Gierl, N. Karoulias, H. Wende, M. StrehleC, Birchmeier, The Zinc-finger factor Insm1 (IA-1) is essential for the development of pancreatic beta cells and intestinal endocrine cells. Genes Dev. 20, 2465–2478 (2006)PubMedPubMedCentral
6.
S.Q. Jia, A. Ivanov, D. Blasevic, T. Muller, B. Purfurst, W. Sun, W. Chen, M.N. Poy, N. Rajewsky, C. Birchmeier, Insm1 cooperates with Neurod1 and Foxa2 to maintain mature pancreatic beta-cell function. EMBO J. 34, 1417–1433 (2015)
7.
A.B. Osipovich, Q.M. Long, E. Manduchi, R. Gangula, S.B. Hipkens, J. Schneider, T. Okubo, C.J. Stoeckert, S. Takada, M.A. Magnuson, Insm1 promotes endocrine cell differentiation by modulating the expression of a network of genes that includes Neurog3 and Ripply3. Development 141, 2939–2949 (2014)PubMedPubMedCentral
8.
J.E. Welcker, L.R. Hernandez-Miranda, F.E. Paul, S.Q. Jia, A. Ivanov, M. SelbachC, Birchmeier, Insm1 controls development of pituitary endocrine cells and requires a SNAG domain for function and for recruitment of histone-modifying factors. Development 140, 4947–4958 (2013)PubMed
9.
H. Wildner, M.S. Gierl, M. Strehle, P. PlaC, Birchmeier, Insm1 (IA-1) is a crucial component of the transcriptional network that controls differentiation of the sympathoadrenal lineage. Development 135, 473–481 (2008)PubMed
10.
M.S. Lan, Q. Li, J. Lu, W.S. Modi, A.L. Notkins, Genomic organization, 5'-upstream sequence, and chromosomal localization of an insulinoma-associated intronless gene, IA-1. J. Biol. Chem. 269, 14170–14174 (1994)PubMed
11.
Q. Li, A.L. Notkins, M.S. Lan, Molecular characterization of the promoter region of a neuroendocrine tumor marker, IA-1. Biochem. Biophys. Res. Commun. 236, 776–781 (1997)PubMed
12.
M.S. Lan, M.B. Breslin, Structure, expression, and biological function of INSM1 transcription factor in neuroendocrine differentiation. FASEBJ 23, 2024–2033 (2009)
13.
N. Pedersen, M.W. Pedersen, M.S. Lan, M.B. Breslin, H.S. Poulsen, The insulinoma-associated 1: a novel promoter for targeted cancer gene therapy for small-cell lung cancer. Cancer Gene Ther. 13, 375–384 (2006)PubMed
14.
E. De Smaele, C. Fragomeli, E. Ferretti, M. Pelloni, A. Po, G. Canettieri, S. Coni, L. Di Marcotullio, A. Greco, M. Moretti, C. Di Rocco, S. Pazzaglia, M. Maroder, I. Screpanti, G. GianniniA, Gulino, An integrated approach identifies Nhlh1 and Insm1 as Sonic Hedgehog-regulated genes in developing cerebellum and medulloblastoma. Neoplasia 10, 89–98 (2008)PubMedPubMedCentral
15.
M.T. Lilo, Y. Chen, R.E. LeBlanc, INSM1 is more sensitive and interpretable than conventional immunohistochemical stains used to diagnose Merkel cell carcinoma. Am. J. Surg. Pathol. 42, 1541–1548 (2018)PubMed
16.
H.W. Wang, M.B. Breslin, C.C. Chen, V. Akerstrom, Q. Zhong, M.S. Lan, INSM1 promoter-driven adenoviral Herpes Simplex Virus thymidine kinase cancer gene therapy for the treatment of primitive neuroectodermal tumors. Hum. Gene Ther. 20, 1308–1318 (2009)PubMedPubMedCentral
17.
T. Zhang, C. Chen, M.B. Breslin, K. Song, M.S. Lan, Extra-nuclear activity of INSM1 transcription factor enhances insulin receptor signaling pathway and Nkx6.1 expression through RACK1 interaction. Cell. Signal. 26, 740–747 (2014)PubMedPubMedCentral
18.
T. Zhang, W.D. Liu, N.A. Saunee, M.B. Breslin, M.S. Lan, Zinc Finger transcription factor INSM1 interrupts Cyclin D1 and CDK4 binding and induces cell cycle arrest. J. Biol. Chem. 284, 5574–5581 (2009)PubMedPubMedCentral
19.
M.B. Breslin, M. Zhu, M.S. Lan, NeuroD1/E47 regulates the e-box element of a novel zinc finger transcription factor, IA-1, in developing nervous system. J. Biol. Chem. 278, 38991–38997 (2003)PubMedPubMedCentral
20.
G. Mellitzer, S. Bonne, R.F. Luco, M. Van de Casteele, N. Lenne-Samuel, P. Collombat, A. Mansouri, J. Lee, M. Lan, D. Pipeleers, F.C. Nielsen, J. Ferrer, G. GradwohlH, Heimberg, IA1 is NGN3-dependent and essential for differentiation of the endocrine pancreas. EMBO J. 25, 1344–1352 (2006)PubMedPubMedCentral
21.
M.B. Breslin, H.W. Wang, A. Pierce, R. Aucoin, M.S. Lan, Neurogenin 3 recruits CBP co-activator to facilitate histone H3/H4 acetylation in the target gene INSM1. FEBS Lett. 581, 949–954 (2007)PubMedPubMedCentral
22.
J.E. Welcker, L.R. Hernandez-Miranda, F.E. Paul, S. Jia, A. Ivanov, M. SelbachC, Birchmeier, Insm1 controls development of pituitary endocrine cells and requires a SNAG domain for function and for recruitment of histone-modifying factors. Development 140, 4947–4958 (2013)PubMed
23.
S.Q. Jia, H. Wildner, C. Birchmeier, Insm1 controls the differentiation of pulmonary neuroendocrine cells by repressing Hes1. Dev. Biol. 408, 90–98 (2015)PubMed
24.
W.H. Tao, Y. Zhang, L.J. Ma, C.J. Deng, H.L. Duan, X.H. Liang, R. Liao, S.Q. Lin, T. Nie, W.Q. Chen, C.C. Wang, C. Birchmeier, S.Q. Jia, Haploinsufficiency of INSM1 impairs postnatal baseline beta-cell mass. Diabetes 67, 2615–2625 (2018)PubMed
25.
C.C. Chen, M.B. Breslin, M.S. Lan, INSM1 increases N-myc stability and oncogenesis via a positive-feedback loop in neuroblastoma. Oncotarget 6, 36700–36712 (2015)PubMedPubMedCentral
26.
G. Mellitzer, S. Bonne, R.F. Luco, M. Van De Casteele, N. Lenne-Samuel, P. Collombat, A. Mansouri, J. Lee, M. Lan, D. Pipeleers, F.C. Nielsen, J. Ferrer, G. GradwohlH, Heimberg, IA1 is NGN3-dependent and essential for differentiation of the endocrine pancreas. EMBO J. 25, 1344–1352 (2006)PubMedPubMedCentral
27.
J. Xie, T. Cai, H. Zhang, M.S. Lan, A.L. Notkins, The zinc-finger transcription factor INSM1 is expressed during embryo development and interacts with the Cbl-associated protein. Genomics 80, 54–61 (2002)PubMedPubMedCentral
28.
A. Duggan, T. Madathany, S.C. de Castro, D. Gerrelli, K. GuddatiJ, Garcia-Anoveros, Transient expression of the conserved zinc finger gene INSM1 in progenitors and nascent neurons throughout embryonic and adult neurogenesis. J. Comp. Neurol. 507, 1497–1520 (2008)PubMed
29.
L.M. Farkas, C. Haffner, T. Giger, P. Khaitovich, K. Nowick, C. Birchmeier, S. Paabo, W.B. Huttner, Insulinoma-associated 1 has a panneurogenic role and promotes the generation and expansion of basal progenitors in the developing mouse neocortex. Neuron 60, 40–55 (2008)PubMed
30.
H. Wildner, M.S. Gierl, M. Strehle, P. Pla, C. Birchmeier, Insm1 (IA-1) is a crucial component of the transcriptional network that controls differentiation of the sympatho-adrenal lineage. Development 135, 473–481 (2008)PubMed
31.
B. Oronsky, P.C. Ma, D. Morgensztern, C.A. Carter, Nothing But NET: A review of neuroendocrine tumors and carcinomas. Neoplasia 19, 991–1002 (2017)PubMedPubMedCentral
32.
P.S. Rush, J.N. Rosenbaum, M. Roy, R.M. Baus, D.D. Bennett, R.V. Lloyd, Insulinoma-associated 1: A novel nuclear marker in Merkel cell carcinoma (cutaneous neuroendocrine carcinoma). J. Cutan. Pathol. 45, 129–135 (2018)PubMed
33.
Y. Takase, Y. Naito, Y. Okabe, Y. Ishida, T. Yamaguchi, H. Abe, K. Murata, T. Ito, M. Tanigawa, A. Kawahara, H. YanoJ, Akiba, Insulinoma-associated protein 1 expression in pancreatic neuroendocrine tumours in endoscopic ultrasound-guided fine-needle aspiration cytology: An analysis of 14 patients. Cytopathology 30, 194–200 (2019)PubMed
34.
S. Mukhopadhyay, J.K. Dermawan, C.P. Lanigan, C.F. Farver, Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical study of 345 cases, including 292 whole-tissue sections. Mod. Pathol. 32, 100–109 (2019)PubMed
35.
A. Yoshida, N. Makise, S. Wakai, A. Kawai, N. Hiraoka, INSM1 expression and its diagnostic significance in extraskeletal myxoid chondrosarcoma. Mod. Pathol. 31, 744–752 (2018)PubMed
36.
M. Tanigawa, M. Nakayama, T. Taira, S. Hattori, Y. Mihara, R. Kondo, H. Kusano, K. Nakamura, Y. Abe, Y. Ishida, Y. Okabe, T. Hisaka, K. Okuda, K. Fujino, T. Ito, A. Kawahara, Y. Naito, R. Yamaguchi, J. Akiba, Y. AkagiH, Yano, Insulinoma-associated protein 1 (INSM1) is a useful marker for pancreatic neuroendocrine tumor. Med. Mol. Morphol. 51, 32–40 (2018)PubMed
37.
L.M. Rooper, R. Sharma, Q.K. Li, P.B. Illei, W.H. Westra, INSM1 demonstrates superior performance to the individual and combined use of synaptophysin, chromogranin and CD56 for diagnosing neuroendocrine tumors of the thoracic cavity. Am. J. Surg. Pathol. 41, 1561–1569 (2017)PubMed
38.
J.N. Rosenbaum, Z.Y. Guo, R.M. Baus, H. Werner, W.M. Rehrauer, R.V. Lloyd, INSM1A anovel immunohistochemical and molecular marker for neuroendocrine and neuroepithelial neoplasms. Am. J. Clin. Pathol. 144, 579–591 (2015)PubMed
43.
C. Chen, A.L. Notkins, M.S. Lan, Insulinoma-associated-1: From neuroendocrine tumor marker to cancer therapeutics. Mol. Cancer Res. 17, 1597–1604 (2019)PubMed
44.
C. Chen, M.B. Breslin, M.S. Lan, INSM1 increases N-myc stability and oncogenesis via a positive-feedback loop in neuroblastoma. Oncotarget 6, 36700–36712 (2015)PubMedPubMedCentral
45.
S. Kobayashi, T. Contractor, E. Vosburgh, Y.C.N. Du, L.H. Tang, R. Clausen, C.R. Harris, Alleles of Insm1 determine whether RIP1-Tag2 mice produce insulinomas or nonfunctioning pancreatic neuroendocrine tumors. Oncogenesis 8, 1–16 (2019)
40.
H. Kajiwara, K. Hirabayashi, M. Miyazawa, N. Nakamura, T. Hirasawa, T. Muramatsu, M. Mikami, M. Yasuda, R.Y. Osamura, Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine carcinoma of uterine cervix. Arch. Gynecol. Obstet. 279, 521–525 (2009)PubMed
46.
M. Petrovic, Z. Bukumiric, V. Zdravkovic, S. Mitrovic, H.D. AtkinsonV, Jurisic, The prognostic significance of the circulating neuroendocrine markers chromogranin A, pro-gastrin-releasing peptide, and neuron-specific enolase in patients with small-cell lung cancer. Med. Oncol. 31, 823 (2014)PubMed
47.
M.S. Lan, E.K. Russell, J. Lu, B.E. Johnson, A.L. Notkins, Ia-1, a new marker for neuroendocrine differentiation in human lung-cancer cell-lines. Cancer Res. 53, 4169–4171 (1993)PubMed
48.
E.F. Rodriguez, S. Chowsilpa, Z. Maleki, Insulinoma-sssociated protein 1 immunostain: A diagnostic tool for pulmonary small cell carcinoma in cytology. Acta Cytol. 62, 333–338 (2018)PubMed
49.
M. Wolf, R. Holle, K. Hans, P. Drings, K. Havemann, Analysis of prognostic factors in 766 patients with small-cell lung-cancer (Sclc) - the role of sex as a predictor for survival. Br. J. Cancer 63, 986–992 (1991)PubMedPubMedCentral
39.
C.C. Chen, M.B. Breslin, M.S. Lan, Ectopic expression of a small cell lung cancer transcription factor, INSM1 impairs alveologenesis in lung development. BMC Pulm. Med. 16, 49 (2016)PubMedPubMedCentral
50.
K. Fujino, Y. Motooka, W.A. Hassan, M.O.A. Abdalla, Y. Sato, S. Kudoh, K. Hasegawa, K. Niimori-Kita, H. Kobayashi, I. Kubota, J. Wakimoto, M. Suzuki, T. Ito, Insulinoma-associated protein 1 is a crucial regulator of neuroendocrine differentiation in lung cancer. Am. J. Pathol. 185, 3164–3177 (2015)PubMed
51.
E.E. Doxtader, S. Mukhopadhyay, Insulinoma-associated protein 1 is a sensitive and specific marker of neuroendocrine lung neoplasms in cytology specimens. Cancer Cytopathol. 126, 243–252 (2018)PubMed
52.
O. Farouk, M.A. Ebrahim, A. Senbel, Z. Emarah, W. Abozeed, M.O. Seisa, S. Mackisack, S.A. Jalil, S. Abdelhady, Breast cancer characteristics in very young Egyptian women <= 35 years. Breast Cancer Target 8, 53–58 (2016)
53.
M.J. Duffy, Serum tumor markers in breast cancer: Are they of clinical value? Clin. Chem. 52, 345–351 (2006)PubMed
54.
L.E. Rosen, P. Gattuso, Neuroendocrine tumors of the breast. Arch. Pathol. Lab. Med. 141, 1577–1581 (2017)PubMed
55.
K.A. Egland, J.J. Vincent, R. Strausberg, B. Lee, I. Pastan, Discovery of the breast cancer gene BASE using a molecular approach to enrich for genes encoding membrane and secreted proteins. Proc. Natl. Acad. Sci. U. S. A. 100, 1099–1104 (2003)PubMedPubMedCentral
56.
N. Bretschneider, H. Brand, N. Miller, A.J. Lowery, M.J. Kerin, F. Gannon, S. Denger, Estrogen induces repression of the breast cancer and salivary gland expression gene in an estrogen receptor alpha-dependent manner. Cancer Res. 68, 106–114 (2008)PubMed
57.
C. Gillett, P. Smith, W. Gregory, M. Richards, R. Millis, G. Peters, D. Barnes, Cyclin D1 and prognosis in human breast cancer. Int. J. Cancer 69, 92–99 (1996)PubMed
58.
B. Zengel, E. Vardar, S. Demir, A. Alacacioglu, H. Postaci, A.G. Denecli, M. Sakizli, Beta-catenin stability, frizzled and cyclin D1 proteins expression in human breast cancer and its relation with their prognosis. EJC Suppl. 7, 288–288 (2009)
59.
B. Zengel, E. Vardar, H. Postaci, S. Kececiler, A. Alacacioglu, A.G. Denecli, M. Sakizli, beta-Catenin Stability, Cyclin D1 and Frizzled proteins expression in human breast cancer and their relation with the prognosis. Turk. Klin. Tip. Bilim. 31, 350–357 (2011)
60.
M. Roy, D.G. Buehler, R.R. Zhang, M.L. Schwalbe, R.M. Baus, M.S. Salamat, R.V. Lloyd, J.N. Rosenbaum, Expression of insulinoma-associated protein 1 (INSM1) and orthopedia homeobox (OTP) in tumors with neuroendocrine differentiation at rare sites. Endocr. Pathol. 30, 35–42 (2019)PubMed
61.
R. Nadal, M. Schweizer, O.N. Kryvenko, J.I. Epstein, M.A. Eisenberger, Small cell carcinoma of the prostate. Nat. Rev. Urol. 11, 213–219 (2014)PubMedPubMedCentral
62.
W. Wang, J.I. Epstein, Small cell carcinoma of the prostate - A morphologic and immunohistochemical study of 95 cases. Am. J. Surg. Pathol. 32, 65–71 (2008)PubMed
63.
Z.X. Xin, Y. Zhang, Z. Jiang, L. Zhao, L.C. Fan, Y.Q. Wang, S.W. Xie, S.G. Xun, Y.J. Zhu, J.H. Pan, Q. Liu, Y.R. Huang, B.J. Dong, W. Xue, Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate. Hum. Pathol. 79, 151–159 (2018)PubMed
64.
S. Uccella, G. Ottini, C. Facco, R. Maragliano, S. Asioli, F. Sessa, S. La Rosa, Neuroendocrine neoplasms of the head and neck and olfactory neuroblastoma. Diagnosis and classification. Pathologica 109, 14–30 (2017)PubMed
65.
C.B. Tempfer, I. Tischoff, A. Dogan, Z. Hilal, B. Schultheis, P. Kern, G.A. Rezniczek, Neuroendocrine carcinoma of the cervix: a systematic review of the literature. BMC Cancer 18, 530 (2018)PubMedPubMedCentral
41.
S. Kuji, R. Watanabe, Y. Sato, T. Iwata, Y. Hirashima, M. Takekuma, I. Ito, M. Abe, R. Nagashio, K. Omae, D. Aoki, T. Kameya, A new marker, insulinoma-associated protein 1 (INSM1), for high-grade neuroendocrine carcinoma of the uterine cervix: Analysis of 37 cases. Gynecol. Oncol. 144, 384–390 (2017)PubMed
66.
K. Kriegsmann, C. Zgorzelski, D. Kazdal, M. Cremer, T. Muley, H. Winter, R. Longuespee, J. Kriegsmann, A. Warth, M. Kriegsmann, Insulinoma-associated protein 1 (INSM1) in thoracic tumors is less sensitive but more specific compared with synaptophysin, chromogranin A, and CD56. Appl. Immunohistochem. Mol. Morphol. 32, 100–109 (2018)
67.
M. Svajdler, R. Mezencev, B. Saskova, O. Ondic, P. Mukensnabl, M. Michal, Triple marker composed of p16, CD56, and TTF1 shows higher sensitivity than INSM1 for diagnosis of pulmonary small cell carcinoma: proposal for a rational immunohistochemical algorithm for diagnosis of small cell carcinoma in small biopsy and cytology specimens. Hum. Pathol. 85, 58–64 (2019)PubMed
68.
C. Leblebii, B.B. Sigirci, C.K. Talu, S.B. Koca, G.E. Huq, CD10, TDAG51, CK20, AR, INSM1, and Nestin expression in the differential diagnosis of trichoblastoma and basal cell carcinoma. Int. J. Surg. Pathol. 27, 19–27 (2019)
42.
A.W.S. Tseng, C.C. Chen, M.B. Breslin, M.S. Lan, Tumor-specific promoter-driven adenoviral therapy for insulinoma. Cell. Oncol. 39, 279–286 (2016)
69.
V. Akerstrom, C. Chen, M.S. Lan, M.B. Breslin, Modifications to the INSM1 promoter to preserve specificity and activity for use in adenoviral gene therapy of neuroendocrine carcinomas. Cancer Gene Ther. 19, 828–838 (2012)PubMed
70.
S.R. Michaelsen, C.L. Christensen, M. Sehested, F. Cramer, T.T. Poulsen, A.V. Patterson, H.S. Poulsen, Single agent- and combination treatment with two targeted suicide gene therapy systems is effective in chemoresistant small cell lung cancer cells. J. Gene Med. 14, 445–458 (2012)PubMed
71.
F. Cramer, C.L. Christensen, T.T. Poulsen, M.A. Badding, D.A. Dean, H.S. Poulsen, Insertion of a nuclear factor kappa B DNA nuclear-targeting sequence potentiates suicide gene therapy efficacy in lung cancer cell lines. Cancer Gene Ther. 19, 675–683 (2012)PubMed
72.
73.
C.C. Chen, M.B. Breslin, M.S. Lan, Sonic hedgehog signaling pathway promotes INSM1 transcription factor in neuroendocrine lung cancer. Cell. Signal. 46, 83–91 (2018)PubMed
74.
C.C. Chen, M.B. Breslin, J.J. Guidry, M.S. Lan, 5-Iodotubercidin represses insulinoma-associated-1 expression, decreases cAMP levels, and suppresses human neuroblastoma cell growth. J. Biol. Chem. 294, 5456–5465 (2019)PubMedPubMedCentral
Metadata
Title
Insulinoma-associated protein 1 (INSM1): a potential biomarker and therapeutic target for neuroendocrine tumors
Authors
B. Mahalakshmi
Rathinasamy Baskaran
M. Shanmugavadivu
Ngoc Tuan Nguyen
Bharath Kumar Velmurugan
Publication date
01-06-2020
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 3/2020
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-020-00505-9

Other articles of this Issue 3/2020

Cellular Oncology 3/2020 Go to the issue

Review

CXCL-10: a new candidate for melanoma therapy?

Original paper

CircRNA BIRC6 promotes non-small cell lung cancer cell progression by sponging microRNA-145

OriginalPaper

Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms

Short Communication

Salivary microRNAs identified by small RNA sequencing as potential predictors of response to intensity-modulated radiotherapy in head and neck cancer patients

Original paper

Dp44mT, an iron chelator, suppresses growth and induces apoptosis via RORA-mediated NDRG2-IL6/JAK2/STAT3 signaling in glioma

Original paper

Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits